Back to search

France· FR:63578537

EVIPLERA 200 mg/25 mg/245 mg, comprimé pelliculé

A medicinal product containing emtricitabine + fumarate de ténofovir disoproxil + rilpivirine (chlorhydrate de), registered in France by GILEAD SCIENCES IRELAND UC (IRLANDE), on the national reimbursement list.

Reimbursed in France (Assurance maladie)

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedEVIPLERA 200 mg/25 mg/245 mg, comprim…ATC—REGISTER NO.FR:63578537PACKS LISTED1CHECKEDSeptember 12, 2026

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
EMTRICITABINE + FUMARATE DE TÉNOFOVIR DISOPROXIL + RILPIVIRINE (CHLORHYDRATE DE)
Manufacturer
GILEAD SCIENCES IRELAND UC (IRLANDE)
Country
France (FR)
ATC code
—
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400921947359
    flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 30 comprimé(s)
    EUR 418.59

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Emtricitabine + fumarate de ténofovir disoproxil + rilpivirine (chlorhydrate de) in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All emtricitabine + fumarate de ténofovir disoproxil + rilpivirine (chlorhydrate de) products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Eviplera
  • Liechtenstein · Eviplera
  • Norway · Eviplera

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/004f583c-fbfd-4574-85d8-f7b5cbdcb650
GET /v1/drugs/004f583c-fbfd-4574-85d8-f7b5cbdcb650?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "63578537",
  "date_amm": "2011-11-28",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/11/737",
  "substance": "EMTRICITABINE + FUMARATE DE TÉNOFOVIR DISOPROXIL + RILPIVIRINE (CHLORHYDRATE DE)",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about emtricitabine + fumarate de ténofovir disoproxil + rilpivirine (chlorhydrate de).

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.